With increasingly rapid timelines for achieving IND-ready processes, a bottleneck has emerged in the provision of toxicology data to support INDs for new therapeutics and hence delivery of FIH studies, as Alejandro Fernandez Martell and James Berrie explain in this article originally published in Drug Target Review.